Stay updated on Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    No substantive updates to the study design, eligibility criteria, primary or secondary outcomes, or sponsor were observed; only minor UI and wording adjustments were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T21:17:49.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    36 days ago
    Change Detected
    Summary
    Major change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).
    Difference
    4%
    Check dated 2025-10-06T05:41:24.000Z thumbnail image
  4. Check
    43 days ago
    Change Detected
    Summary
    Update of the page version from v3.0.2 to v3.1.0.
    Difference
    0.1%
    Check dated 2025-09-29T03:07:11.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    Updated from v3.0.1 to v3.0.2; removed the 'Back to Top' element.
    Difference
    0.2%
    Check dated 2025-09-14T19:05:16.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The page has updated the citation for a study on Pembrolizumab in relapsed or refractory Hodgkin lymphoma, changing the publication date and revision number.
    Difference
    0.8%
    Check dated 2025-09-07T15:06:15.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated to include new information on Hodgkin lymphoma treatments, specifically mentioning pembrolizumab and Brentuximab Vedotin, along with a detailed citation of a relevant study. Additionally, the facility name and location have been added, while several terms related to previous treatments and locations have been removed.
    Difference
    7%
    Check dated 2025-08-31T11:44:35.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial page.